Cardiol Therapeutics (CRDL) Enterprise Value (2020 - 2026)
Cardiol Therapeutics (CRDL) posted Enterprise Value of -$20.2 million for Q1 2026, down 31.4% on a QoQ basis from -$15.4 million in Q4 2025, and down 24.31% year-over-year from -$26.7 million in Q1 2025.
Cardiol Therapeutics (CRDL) Enterprise Value (2020 - 2026) Analysis & Trends
Cardiol Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$20.2 million for Q1 2026.
- Quarterly Enterprise Value fell 24.31% year-over-year to -$20.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.2 million (down 24.31% YoY) and the FY2025 annual result came in at -$15.4 million, up 29.84% from the prior year.
- Enterprise Value was -$20.2 million for Q1 2026 at Cardiol Therapeutics, down from -$15.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$8.4 million in Q3 2025 and bottomed at -$59.1 million in Q1 2022.
- A 5-year average of -$28.2 million and a median of -$21.9 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value slumped 120.75% — and 2024, when it surged 61.49%.
- Cardiol Therapeutics' Enterprise Value stood at -$43.8 million in 2022, then surged by 41.43% to -$25.7 million in 2023, then climbed by 14.68% to -$21.9 million in 2024, then climbed by 29.84% to -$15.4 million in 2025, then sank by 31.4% to -$20.2 million in 2026.
- Business Quant data shows CRDL's Enterprise Value at -$20.2 million in Q1 2026, -$15.4 million in Q4 2025, and -$8.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | -1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -4.05 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -2.15 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -1.32 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -428.00 Mn |
| 10 | Cardiol Therapeutics | 134.05 Mn | 134.05 Mn | - | -20.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.18 Mn |
| Dec 31, 2025 | -15.36 Mn |
| Sep 30, 2025 | -8.45 Mn |
| Jun 30, 2025 | -13.13 Mn |
| Mar 31, 2025 | -16.23 Mn |
| Dec 31, 2024 | -21.89 Mn |
| Sep 30, 2024 | -11.64 Mn |
| Jun 30, 2024 | -17.56 Mn |
| Mar 31, 2024 | -21.20 Mn |
| Dec 31, 2023 | -25.66 Mn |
| Sep 30, 2023 | -30.24 Mn |
| Jun 30, 2023 | -33.46 Mn |
| Mar 31, 2023 | -36.59 Mn |
| Dec 31, 2022 | -43.81 Mn |
| Sep 30, 2022 | -50.25 Mn |
| Jun 30, 2022 | -55.26 Mn |
| Mar 31, 2022 | -59.09 Mn |
| Dec 31, 2021 | -66.56 Mn |
| Sep 30, 2021 | -22.76 Mn |
| Jun 30, 2021 | -26.62 Mn |